Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide AptamerJessica Gobbo, Carmen Garrido|JNCI Journal of the National Cancer Institute|2015Cited by 196
Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkersMohammed I. Y. Elmallah, Carmen Garrido|Molecular Oncology|2022Cited by 83
Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapyGustavo Jabor Gozzi, Carmen Garrido|Cell Death and Differentiation|2019Cited by 64
CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorderAurélie de Thonel, Valérie Mezger, Agathe Duchateau et al.|Nature Communications|2022Cited by 20
CBP/EP300-dependent acetylation and stabilization of HSF2 are compromised in the rare disorder, Rubinstein-Taybi syndromeAurélie de Thonel, Valérie Mezger, Johanna K. Ahlskog et al.|bioRxiv (Cold Spring Harbor Laboratory)|2018Cited by 2